Remifentanil Pharmacokinetics in Obese versus Lean Patients

Background Remifentanil is a short-acting opioid whose pharmacokinetics have been characterized in detail. However, the impact of obesity on remifentanil pharmacokinetics has not been specifically examined. The goal of this study was to investigate the influence of body weight on remifentanil pharmacokinetics. Methods Twelve obese and 12 matched lean subjects undergoing elective surgery received a 1-min remifentanil infusion after induction of anesthesia. Arterial blood samples were collected for determination of remifentanil blood concentrations. Each subject's pharmacokinetic parameters were estimated by fitting a two-compartment model to the concentration versus time curves. Nonlinear mixed-effects population models examining the influence of lean body mass (LBM) and total body weight (TBW) were also constructed. Clinical simulations using the final population model were performed. Results The obese patient cohort reached substantially higher remifentanil concentrations. The individual pharmacokinetic parameters of a two-compartment model were not significantly different between the obese versus lean cohorts (unless normalized to TBW). The final population model scaled central clearance and the central and peripheral distribution volumes to LBM. The simulations illustrated that remifentanil pharmacokinetics are not grossly different in obese versus lean subjects and that TBW based dosing in obese patients can result in excessively high remifentanil concentrations. Conclusions The essential findings of the study are that remifentanil's pharmacokinetics are not appreciably different in obese versus lean subjects and that remifentanil pharmacokinetic parameters are therefore more closely related to LBM than to TBW. Clinically this means that remifentanil dosing regimens should be based on ideal body weight (or LBM) and not TBW.

[1]  D. Greenblatt,et al.  Pharmacokinetics of Drugs in Obesity , 1982, Clinical pharmacokinetics.

[2]  N. Wulfsohn.  Halothane dosage based on lean body mass. , 1969, British journal of anaesthesia.

[3]  P. Glass,et al.  Preliminary Pharmacokinetics and Pharmacodynamics of an Ultra‐Short‐Acting Opioid: Remifentanil (GI87084B) , 1993, Anesthesia and analgesia.

[4]  P. Glass.  Remifentanil: a new opioid. , 1995, Journal of clinical anesthesia.

[5]  T. Egan,et al.  Predicting difficult laryngoscopy for tracheal intubation: an approach to airway assessment. , 1993, Ma zui xue za zhi = Anaesthesiologica Sinica.

[6]  K. Flegal,et al.  Increasing Prevalence of Overweight Among US Adults: The National Health and Nutrition Examination Surveys, 1960 to 1991 , 1994 .

[7]  T. Egan.  Remifentanil Pharmacokinetics and Pharmacodynamics , 1995, Clinical pharmacokinetics.

[8]  A. Bjorksten,et al.  Effect of body build on the clearance of atracurium: implication for drug dosing. , 1993 .

[9]  K T Muir,et al.  Pharmacokinetics of Remifentanil (GI87084B) and Its Major Metabolite (GI90291) in Patients Undergoing Elective Inpatient Surgery , 1993, Anesthesiology.

[10]  S L Shafer,et al.  Pharmacokinetics, pharmacodynamics, and rational opioid selection. , 1991, Anesthesiology.

[11]  D. Morgan,et al.  Lean Body Mass as a Predictor of Drug Dosage , 1994, Clinical pharmacokinetics.

[12]  N. Wulfsohn,et al.  Thiopentone dosage based on lean body ms. , 1969, British journal of anaesthesia.

[13]  P. Glass,et al.  Pharmacokinetics Anesthesiologists, and Pharmacodynamics of Remifentanil in Persons with Renal Failure Compared with Healthy Volunteers , 1997 .

[14]  S. Shafer,et al.  Pharmacokinetic Parameters Relevant to Recovery from Opioids , 1994, Anesthesiology.

[15]  David J. Hermann,et al.  The Pharmacokinetics of the New Short‐acting Opioid Remifentanil (GI87084B) in Healthy Adult Male Volunteers , 1993, Anesthesiology.

[16]  K T Muir,et al.  Pharmacokinetics and Pharmacodynamics of Remifentanil in Volunteer Subjects with Severe Liver Disease , 1996, Anesthesiology.

[17]  D R Stanski,et al.  Population pharmacokinetics of alfentanil: the average dose-plasma concentration relationship and interindividual variability in patients. , 1987, Anesthesiology.

[18]  T. Egan,et al.  Intravenous drug delivery systems: toward an intravenous "vaporizer". , 1996, Journal of clinical anesthesia.

[19]  S L Shafer,et al.  Pharmacokinetics and Pharmacodynamics of Remifentanil: II. Model Application , 1997, Anesthesiology.

[20]  Juliana Barr,et al.  Remifentanil Versus Alfentanil: Comparative Pharmacokinetics and Pharmacodynamics in Healthy Adult Male Volunteers , 1996, Anesthesiology.

[21]  J. Kehayias,et al.  The meaning and measurement of lean body mass. , 2009, Nutrition reviews.

[22]  W. Young,et al.  Pharmacokinetics of Sufentanil in Obese Patients , 1991, Anesthesia and analgesia.

[23]  L B Sheiner,et al.  The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods. , 1984, Drug metabolism reviews.

[24]  I. M. Davis,et al.  Determination of remifentanil in human blood by liquid-liquid extraction and capillary GC-HRMS-SIM using a deuterated internal standard. , 1994, Journal of pharmaceutical and biomedical analysis.

[25]  Thomas W. Schnider,et al.  Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development , 1997 .

[26]  M. A. Hughes,et al.  Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs. , 1992, Anesthesiology.